BACE1 Inhibitor Development for Alzheimer's Disease Therapeutics

The aspartyl protease BACE1 has long been recognised as the rate-limiting step in the generation of neurotoxic β-amyloid peptides from amyloid precursor protein (APP), making it a compelling therapeutic target for disease-modifying interventions in Alzheimer’s disease. Over the past two decades, medicinal chemists have crafted diverse small molecules and biologics designed to inhibit BACE1, with an emphasis on high potency, selectivity over related proteases and central nervous system penetration. Early clinical trials of first-generation inhibitors demonstrated robust reductions in cerebrospinal fluid Aβ levels but were complicated by off-target liabilities, suboptimal pharmacokinetics and mechanistic safety concerns, including ophthalmic effects and impact on cognitive function. This has prompted a paradigm shift towards structure-guided optimisation, advanced chemical proteomics for safety profiling and novel modalities such as peptide-based inhibitors and repurposed agents identified through in silico screening. The emerging portfolio of BACE1 inhibitors reflects an ever more sophisticated integration of pharmacological insights, ADME optimisation and safety assessments to balance maximal Aβ suppression with a favourable side-effect profile. Continued global efforts aim to define the therapeutic window for prevention and early intervention in preclinical stages of Alzheimer’s disease.

Research from Nature Portfolio

Recent studies have leveraged chemoproteomic platforms to delineate unintended interactions of BACE1 inhibitors at the cellular level. One seminal work employed a photoaffinity probe to map target engagement in human cell lines, revealing that several advanced BACE1 compounds also bind and inhibit cathepsin D with higher potency than anticipated. Quantitative engagement of this off-target protease correlated with ocular toxicity in animal models and underscored the importance of comprehensive proteome-wide profiling in early-stage drug development. These insights have guided the refinement of inhibitor scaffolds, informing structure-activity relationships that mitigate cathepsin D engagement while preserving on-target efficacy against BACE1.

BACE1 Inhibitor Development for Alzheimer's Disease Therapeutics publication trend

The graph below shows the total number of articles in bace1 inhibitor development for alzheimer's disease therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

BACE1: β-site APP cleaving enzyme 1, an aspartyl protease initiating production of β-amyloid peptides involved in Alzheimer’s pathology.

Amyloid precursor protein (APP): Membrane protein cleaved by secretases to generate β-amyloid peptides.

Blood–brain barrier (BBB): Selective endothelial interface regulating passage of molecules into the central nervous system.

In silico: Computational modelling techniques used to predict molecular interactions and pharmacological properties.

Off-target activity: Unintended interaction of a compound with non-intended biological targets, potentially causing adverse effects.

References

1. β-Secretase-1: In Silico Drug Reposition for Alzheimer’s Disease. International Journal of Molecular Sciences (2023).
2. Design, in silico and pharmacological evaluation of a peptide inhibitor of BACE-1. Frontiers in Pharmacology (2023).
3. Multitargeted Virtual Screening and Molecular Simulation of Natural Product-like Compounds against GSK3β, NMDA-Receptor, and BACE-1 for the Management of Alzheimer’s Disease. Pharmaceuticals (2023).
4. The Alzheimer's disease β-secretase enzyme, BACE1. Molecular Neurodegeneration (2007).
5. BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease. Alzheimer's Research & Therapy (2014).
6. Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors. Nature Communications (2016).
7. The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease. EMBO Molecular Medicine (2018).